Augmented antitumor effects of combination therapy with interleukin-12, cisplatin, and tumor necrosis factor-α in a murine melanoma model

Anticancer Research

Volumn 17, Issue 6 D, 1997, Pages 4493-4498

  Zagozdzon, Radosław ^a   Stokłosa, Tomasz ^a   Gołab, Jakub ^a   Giermasz, Adam ^a   Dabrowska, Anna ^a   Lasek, Witold ^a   Jakóbisiak, Marek ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Cisplatin; Interleukin 12; Melanoma; Mice; Tumor necrosis factor

Indexed keywords

CISPLATIN; RECOMBINANT INTERLEUKIN 12; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; INTRAPERITONEAL DRUG ADMINISTRATION; INTRATUMORAL DRUG ADMINISTRATION; MALE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CELL DIVISION; CISPLATIN; COMBINED MODALITY THERAPY; DRUG SYNERGISM; IMMUNOTHERAPY; INTERLEUKIN-12; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; RECOMBINANT PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 2642599039     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. D'Andrea A, Rengaraju M, Valiante NM, Chehimi J, Kubin M, Aste M, Chan SH, Kobayashi M, Young D, Nickbarg E, Chizzonite R, Wolf SF and Trinchieri G: Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells. J Exp Med 176: 1387-1398, 1992.
2. Gately MK, Desai BB, Wolitzky AG, Quinn PM, Dwyer CM, Podlaski FJ, Familletti PC, Sinigaglia F, Chizzonite R, Gubler U and Stern AS: Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J Immunol 147: 874-882, 1991.
3. Kobayashi M, Fitz L, Ryan M, Hewick RM, Clark SC, Chan S, Loudon R, Sherman F, Perussia B and Trinchieri G: Identification and purification of natural killer stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 770: 827-845, 1989.
4. Perussia B, Chan SH, D'Andrea A, Tsuji K, Santoli D, Pospisil M, Young D, Wolf SF and Trinchieri G: Natural killer (NK) cell stimulatory factor or IL-12 has differential effects on the proliferation of TCR-αβ+, TCR-γδ+ T lymphocytes, and NK cells. J Immunol 149: 3495-3502, 1992.
5. Robertson MJ, Soiffer RJ, Wolf SF, Manley TJ, Donahue C, Young D, Herrmann SH and Ritz J: Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolitic activity and proliferation of NK cells are differentially regulated by NKSF. J Exp Med 175: 779-788, 1992.
6. Chan SH, Perussia B, Gupta JW, Kobayashi M, Pospisil M, Young HA, Wolf SF, Young D, Clark SC and Trinchieri G: Induction of interferon y production by natural killer cell stimulatory factor: characterisation of the responder cells and synergy with other inducers. J Exp Med 173: 869-879, 1991.
7. Manetti R, Parronchi P, Giudizi MG, Piccinni MP, Maggi E, Trinchieri G and Romagnani S: Natural killer stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immnue responses and inhibits the developement of IL-4-producing Th cells. J Exp Med 177: 1199-1204, 1993.
8. Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M, Wolf SF and Gately MK: Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 178: 1223-1230, 1993.
9. Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, Brunda MJ, Gately MK, Wolf SF, Schreiber RD, Storkus WJ and Lotze MT: Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J Immunol 153: 1697-1706, 1994.
10. Eng VM, Car BD, Schnyder B, Lorenz M, Lugli S, Aguet M, Anderson TD, Ryffel B and Quesniaux VF: The stimulatory effects of interleukin (IL)-12 on hematopoiesis are antagonized by IL-12-induced interferon Y in vivo. J Exp Med 181: 1893-1898, 1995.
11. Tare NS, Bowen S, Warrier RR, Carvajal DM, Benjamin WR, Riley JH, Anderson TD and Gately MK: Administration of recombinant interleukin-12 to mice suppresses hematopoiesis in the bone marrow but enhances hematopoiesis in the spleen. J Interferon Cytokine Res 15: 377-383, 1995.
12. Sodhi A, Singh RK and Pai K: Activation of murine macrophages by tumor necrosis factor, interleukin-1, interferon-γ and cisplatin. Immunol Lett 26: 45-50, 1990.
13. Yamaue H, Tanimura H, Noguchi K, Iwahashi M, Tsunoda T, Tani M, Tamai M, Hotta T, Mizobata S and Arii K: Cisplatin treatment renders tumor cells more susceptible to attack by lymphokine-activated killer cells. J Clin Lab Immunol 35: 165-170, 1991.
14. Asher A, Mule JJ, Reichert CM, Shiloni E and Rosenberg SA: Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 138: 963-974, 1987.
15. Havell EA, Fiers W and North RJ: The antitumor function of tumor necrosis factor (TNF), I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity. J Exp Med 167: 1067-1085, 1988.
16. Asher AL, Mule JJ and Rosenberg SA: Recombinant human tumor necrosis factor mediates regression of a murine sarcoma in vivo via Lyt-2+ cells. Cancer Immunol Immunother 28: 153-156, 1989.
17. Thom AK, Alexander HR, Andrich MP, Barker WC, Rosenberg SA and Fraker DL: Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon y, and melphalan. J Clin Oncol 13: 264-273, 1995.
18. Seibel NL, Dinndorf PA, Bauer M, Sondel PM, Hammond GD and Reaman GH: Phase I study of tumor necrosis factor-α and actinomycin D in pediatric patients with cancer: a Children's Cancer Group study. J Immunother 16: 125-131, 1994.
19. Kettelhut IC, Fiers W and Goldberg AL: The toxic effects of tumor necrosis factor in vivo and their prevention by cyclooxygenase inhibitors. Proc Natl Acad Sci USA 84: 42734277, 1987.
20. Tracey KJ, Beutler B, Lowry SF, Merryweather J, Wolpe S, Milsark IW, Hariri RJ, Fahey TJ 3rd, Zentella A, Albert JD, Shires GT and Cerami A: Shock and tissue injury induced by recombinant human cachectin. Science 234: 470-474, 1986.
21. Brouckaert PG, Leroux-Roels GG, Guisez Y, Tavernier J and Fiers W: In vivo antitumour activity of recombinant human and murine TNF, alone and in combination with murine IFN-γ, on a syngeneic murine melanoma. Int J Cancer 38: 763-769, 1986.
22. Lasek W, Wańkowicz A, Kuc K, Feleszko W, Giermasz A and Jakóbisiak M: Augmentation of antitumor efficacy by the combination of actinomycin D with tumor necrosis factor-alpha and interferon-gamma on a melanoma model in mice. Oncology 53: 31-37, 1996.
23. Clark S, McGuckin MA, Hurst T and Ward BG: Effect of interferon γ and tumour necrosis factor a on sensivity to cisplatin in ovarian carcinoma cell lines. Cancer Immunol Immunother 39: 100-104, 1994.
24. Kłysik J, Konarzewska-Zglińska A, Gałażka G, Uznański B, Okruszek A, Guga P, Wilk A, Koziołkiewicz M, Tchórzewski H, Zembala M and Stec WJ: Synthesis and expression in E. coli of the gene for human tumor necrosis factor (h alpha TNF). Arch Immunol Ther Exp 39: 349-355, 1991.
25. Lasek W, Giermasz A, Kuc K, Wańkowicz A, Feleszko W, Gołab J, Zagożdżon R, Stokłosa T and Jakóbisiak M: Potentiation of the antitumor effect of actinomycin D by tumor necrosis factor a in mice: correlation between in vitro and in vivo results. Int J Cancer 66: 374-379, 1996.
26. Colombo MP, Vagliani M, Spreafico F, Parenza M, Chiodoni C, Melani C and Stoppacciaro A: Amount of interleukin 12 available at the tumor site is critical for tumor regression. Cancer Res 56: 2531-2534, 1996.
27. Brunda MJ, Luistro L, Rumennik L, Wright RB, Dvorozniak M, Aglione A, Wiggington JM, Wiltrout RH, Hendrzak JA and Palleroni AV: Antitumor activity of interleukin 12 in preclinical models. Cancer Chemother Pharmacol 38: S16-S21, 1996.
28. Marth C, Helmberg M, Mayer I, Fuith LC, Daxenbichler G and Dapunt O: Effects of biological response modifiers on ovarian carcinoma cell lines. Anticancer Res 9: 461-468, 1989
29. Saito T, Berens MF and Welander CF: Interferon-gamma and cytotoxic agents studied in combination using a soft agarose human tumor clogenic assay. Cancer Chemother Pharmacol 19: 233-239, 1987.
30. Schadendorf D, Jurgovsky K, Worm M and Czarnetzki BM: In vitro sensitivity of human melanoma cells to chemotherapeutic agents and interferons. Melanoma Res 4: 243-249, 1994.
31. Brunda MJ, Luistro L, Hendrzak JA, Fountoulakis M, Garotta G and Gately MK: Role of interferon-γ in mediating the antitumor efficacy of interleukin-12. J Immunother 17: 71-77, 1995.